Shionogi plans to acquire IntraBio for $2 billion, adding AQNEURSA and expanding its rare neurological disease portfolio.
Written By: Rishabh Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
Shionogi & Co., Ltd. has agreed to acquire IntraBio Inc., a biopharmaceutical company focused on rare neurodegenerative and genetic neurological diseases. Announced on October 5, 2026, the transaction would be completed through Shionogi Inc., the company’s U.S. subsidiary, which would acquire all outstanding shares of IntraBio and make it a wholly owned subsidiary.
The acquisition would add AQNEURSA® (levacetylleucine), an approved therapy for neurological manifestations of Niemann-Pick disease type C (NPC) and for ataxia in patients with Ataxia-Telangiectasia (A-T), to Shionogi’s portfolio.
AQNEURSA Expands into Ataxia-Telangiectasia
AQNEURSA is approved in the United States for neurological manifestations of NPC and was approved in the European Union in January 2026 for neurological symptoms associated with the disease.
On September 18, 2026, the U.S. Food and Drug Administration granted supplemental approval for AQNEURSA for the treatment of ataxia in adults and pediatric patients with A-T. According to the companies, it is the first and only approved treatment for ataxia in patients with A-T.
The FDA decision was supported by Phase 3 study (NCT06673056), a randomized, double-blind, placebo-controlled crossover study involving 73 patients aged 4 years and older with A-T. AQNEURSA is also being evaluated by the European Medicines Agency for adults and pediatric patients with A-T.
A-T is a rare inherited neurodegenerative disorder caused by variants in the ATM gene and typically begins during childhood. Progressive impairment of movement, coordination, speech and eye movements can occur alongside immune dysfunction, recurrent infections and pulmonary complications. The disease is also associated with substantially increased risks of leukemia and lymphoma.
Established Development in Niemann-Pick Disease Type C
AQNEURSA’s development in NPC includes the pivotal Phase 3 study (NCT05163288), which supported its U.S. FDA approval for neurological manifestations of the disease.
NPC is an ultra-rare, progressive disorder caused by variants in the NPC1 or NPC2 genes. These variants disrupt intracellular lipid trafficking and can lead to neurological and systemic manifestations ranging from infancy through adulthood. The variable presentation of the disease can also make diagnosis challenging.
AQNEURSA, also known in clinical development as N-acetyl-L-leucine, has therefore been developed to address neurological manifestations associated with these rare disorders.
Expanding Rare Disease Capabilities
The transaction would give Shionogi global rights to AQNEURSA, including its intellectual property and commercialization rights. Commercialization is already underway in the United States for NPC, while the A-T indication provides an additional opportunity to expand the therapy’s clinical reach.
The deal also builds on Shionogi’s recent expansion in rare diseases. In April 2026, the company acquired global rights to edaravone, marketed as RADICAVA® in the United States and RADICUT® in Japan.
IntraBio would additionally bring development capabilities and programs in Pompe disease, Fragile X syndrome and Jordan’s syndrome, alongside other early-stage programs in rare neurodegenerative and genetic neurological diseases.
Shionogi CEO Isao Teshirogi said the transaction would deepen the company’s commitment to rare-disease communities. Shionogi Inc. President and CEO Nathan McCutcheon highlighted the opportunity to build on IntraBio’s work in NPC and expand access to AQNEURSA for patients with A-T who have historically had limited treatment options.
Transaction Terms and Financials
Under the agreement, Shionogi Inc. will acquire all outstanding shares of IntraBio for $2 billion in upfront consideration payable to IntraBio shareholders.
IntraBio reported net sales of $67.9 million in fiscal 2025, compared with $3.5 million in 2024. Its 2025 operating loss was $35.3 million, while its net loss was $35.8 million.
Shionogi said the impact of the transaction on its consolidated financial results for the fiscal year ending March 2027 remains under review.
Closing Expected Between November and December 2026
The transaction is currently expected to close between November and December 2026, subject to customary closing conditions, including applicable competition-law waiting periods and required regulatory approvals or clearances.
Until completion, IntraBio will remain a separate company.
If completed as planned, the acquisition would add an established rare-disease therapy and additional neurological development programs to Shionogi’s portfolio, supporting the company’s broader strategy to expand its presence in rare neurological and genetic diseases.
Reference
Shionogi Continues Rare Disease Expansion with Planned Acquisition of IntraBio Inc., Shionogi, 05 October 2026
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.